Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction

被引:149
作者
Buresly, K
Eisenberg, MJ
Zhang, X
Pilote, L
机构
[1] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada
[2] Jewish Gen Hosp, Montreal, PQ, Canada
关键词
D O I
10.1001/archinte.165.7.784
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Combinations of aspirin with thienopyridine derivatives (clopidogrel bisulfate or ticlopidine hydrochloride) and/or warfarin sodium are increasingly being used in various cardiac conditions. However, little is known about the bleeding risks associated with these combinations, particularly in elderly individuals at the population level. This study estimates the bleeding risks associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients. Methods: We conducted a population-based observational cohort study using linked administrative databases. A total of 21443 elderly survivors of acute myocardial infarction between 1996 and 2000 were studied. Patients were divided into 5 groups according to drug exposure: aspirin alone, warfarin alone, aspirin plus a thienopyridine derivative (antiplatelet combination), aspirin plus warfarin (anticoagulant combination), and aspirin plus warfarin plus a thienopyridine derivative (3-drug combination). Hospitalizations for bleeding events were examined. Results: Hospitalizations for bleeding were observed in 1428 patients (7%). Compared with rates of patients receiving aspirin alone (0.03 per patient-year) I rates of bleeding were higher among patients receiving the antiplatelet combination (0.07 per patient-year), the anticoagulant combination (0.08 per patient-year), and the 3-drug combination (0.09 per patient-year). Compared with aspirin alone, the adjusted odds ratios (95% confidence intervals) for bleeding were 1.65 (1.02-2.73) for patients receiving the antiplatelet combination and 1.92 (1.28-2.87) for patients receiving the anticoagulant combination. Only 1 of 141 patients in the 3-drug combination group had a bleeding event. Conclusion: In practice, antiplatelet and anticoagulant combinations lead to modest increases in bleeding risk in elderly patients, but the overall risk is small.
引用
收藏
页码:784 / 789
页数:6
相关论文
共 19 条
[1]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[2]   Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement [J].
Berger, PB ;
Bell, MR ;
Hasdai, D ;
Grill, DE ;
Melby, S ;
Holmes, DR .
CIRCULATION, 1999, 99 (02) :248-253
[3]   Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting - The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study [J].
Bertrand, ME ;
Legrand, V ;
Boland, J ;
Fleck, E ;
Bonnier, J ;
Emmanuelson, H ;
Vrolix, M ;
Missault, L ;
Chierchia, S ;
Casaccia, M ;
Niccoli, L ;
Oto, A ;
White, C ;
Webb-Peploe, M ;
Van Belle, E ;
McFadden, EP .
CIRCULATION, 1998, 98 (16) :1597-1603
[4]   Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinoilysis for acute myocardial infarction - Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 trial [J].
Brouwer, MA ;
van den Bergh, PJPC ;
Aengevaeren, WRM ;
Veen, G ;
Luijten, HE ;
Hertzberger, DP ;
van Boven, AJ ;
Vromans, RPJW ;
Uijen, GJH ;
Verheugt, FWA .
CIRCULATION, 2002, 106 (06) :659-665
[5]   Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction - Primary results of the CHAMP study [J].
Fiore, LD ;
Ezekowitz, MD ;
Brophy, MT ;
Lu, D ;
Sacco, J ;
Peduzzi, P .
CIRCULATION, 2002, 105 (05) :557-563
[6]  
GILKS WR, 1996, CHAIN MONTE CARLO PR
[7]   Warfarin, aspirin, or both after myocardial infarction. [J].
Hurlen, M ;
Abdelnoor, M ;
Smith, P ;
Erikssen, J ;
Arnesen, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :969-974
[8]   A clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting [J].
Leon, MB ;
Baim, DS ;
Popma, JJ ;
Gordon, PC ;
Cutlip, DE ;
Ho, KKL ;
Giambartolome, A ;
Diver, DJ ;
Lasorda, DM ;
Williams, DO ;
Pocock, SJ ;
Kuntz, RE .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (23) :1665-1671
[9]  
Levy AR, 1999, CAN J CARDIOL, V15, P1277
[10]   Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: A meta-analysis [J].
Massel, D ;
Little, SH .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :569-578